Advertisement
Advertisement
ALLR
Allarity Therapeutics, Inc. Common Stock
1.39
USDSponsored
-0.01
-0.71%
Aug 07, 15:59 UTC -4
Closed
After-Market
1.40
+0.01
+0.72%
ALLR Earnings Reports
Positive Surprise Ratio
ALLR beat 9 of 14 last estimates.
64%
Next Report
Next Week
Date of Next Report
Aug 15, 2026
Estimate for Q2 26 (Revenue/ EPS)
--
/-$0.25
Implied change from Q1 26 (Revenue/ EPS)
-100.00%
/+47.06%
Implied change from Q2 25 (Revenue/ EPS)
--
/+66.67%
Allarity Therapeutics, Inc. Common Stock earnings per share and revenue
On May 15, 2026, ALLR reported earnings of -0.17 USD per share (EPS) for Q1 26, beating the estimate of -0.22 USD, resulting in a 24.24% surprise. Revenue reached 25.00 thousand, compared to an expected --, with a 0.00% difference. The market reacted with a +5.93% price change (close before vs. close after earnings).
Looking ahead to Q2 26, -- analysts forecast an EPS of -0.25 USD, with revenue projected to reach -- USD, implying an increase of 47.06% EPS, and decrease of -100.00% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Cytokinetics Inc.
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$1.67
Actual
-$1.50
Surprise
+10.35%
Celldex Therapeutics, Inc
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$1.07
Actual
-$0.94
Surprise
+12.79%
ANI Pharmaceuticals, Inc.
Report Date
Aug 07, 2026 For Q2 26
Estimate
$2.09
Actual
$2.21
Surprise
+5.69%
Zymeworks Inc.
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.46
Actual
-$0.62
Surprise
-32.31%
Intellia Therapeutics, Inc
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.81
Actual
-$0.80
Surprise
+1.86%
Monte Rosa Therapeutics, Inc. Common Stock
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.39
Actual
-$0.43
Surprise
-9.58%
CytomX Therapeutics, Inc.
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.07
Actual
-$0.09
Surprise
-13.78%
Verastem, Inc.
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.44
Actual
-$0.35
Surprise
+20.69%
ALX Oncology Holdings Inc. Common Stock
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.14
Actual
-$0.13
Surprise
+11.08%
Arcturus Therapeutics Holdings Inc. Common Stock
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$1.01
Actual
-$0.84
Surprise
+17.53%
FAQ
What were Allarity Therapeutics, Inc. Common Stock's earnings and revenue for the latest quarter Q1 2026?
For Q1 2026, Allarity Therapeutics, Inc. Common Stock reported EPS of -$0.17, beating estimates by 24.24%, and revenue of $25.00K, 0% as expectations.
How did the market react to Allarity Therapeutics, Inc. Common Stock's Q1 2026 earnings?
The stock price moved up 5.93%, changed from $1.35 before the earnings release to $1.43 the day after.
When is Allarity Therapeutics, Inc. Common Stock expected to report next?
The next earning report is scheduled for Aug 15, 2026.
What are the forecasts for Allarity Therapeutics, Inc. Common Stock's next earnings report?
Based on --
analysts, Allarity Therapeutics, Inc. Common Stock is expected to report EPS of -$0.25 and revenue of -- for Q2 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement